In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-κB activation

International Immunopharmacology

Volumn 2, Issue 10, 2002, Pages 1451-1464

  Diegel, Michael L ^a   Nadler, Steven G ^a   Kiener, Peter A ^a,b  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

15 Deoxyspergulin; Antigen presentation; Peptide; Superantigen NF B

Indexed keywords

15 DEOXYSPERGUALIN; B7 ANTIGEN; CD11B ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; PEPTIDE; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GUANIDINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MEMBRANE ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, SURFACE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; NF-KAPPA B; T-LYMPHOCYTES;

EID: 0036711069     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00090-5     Document Type: Article

References (49)

1. Alegre M., Sattar H.A., Herold K.C., Smith J., Tepper M.A., Bluestone J.A. Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation. 57:1994;1786-1794.
2. Jung S., Toyka K.V., Hartung H.P. Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat. Clin. Exp. Immunol. 98:1994;494-502.
3. Hotta O., Furuta T., Chiba S., Yusa N., Taguma Y. Immunosuppressive effect of deoxyspergulin in proliferative glomerulonephritis. Am. J. Kidney Dis. 34:1999;894-901.
4. Haga M., Tsuchida M., Hirahara H., Watanabe T., Hayashi J.I., Watanabe H.et al. Synergistic effects of anti-T cell receptor monoclonal antibody and 15-deoxyspergulin on cardiac xenograft survival in a mouse to rat model. Transplantation. 69:2000;2613-2621.
5. Ramos E.L., Nadler S.G., Grasela D.M., Kelley S.L. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant. Proc. 28:1996;873-875.
6. Thomas F.T., Tepper M.A., Thomas J.M., Haisch C.E. 15-Deoxyspergualin: a novel immunosuppressive drug with clinical potential. Ann. N.Y. Acad. Sci. 685:1993;175-192.
7. Amemiya H. 15-Deoxyspergulin: a newly developed immunosuppressive agent and its mechanims of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. Artif. Organs. 8:1996;832-835.
8. Tepper M.A., Nadler S.G., Esselstyn J.M., Sterbenz K.G. Deoxyspergulin inhibits kappa light chain expression in 70/Z3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J. Immunol. 155:1995;2427-2436.
9. Goral J., Mathews H.L., Nadler S.G., Clancy J. Reduced levels of Hsp70 result in a therapeutic effect of 15-deoxyspergualin on acute graft-versus-host disease in (DA×LEW)F1 rats. Immunobiology. 202:2000;254-266.
10. Nadler S.G., Dischino D.D., Malacko A.R., Cleaveland J.S., Fujihara S.M., Marquardt H. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem. Biophys. Res. Commun. 253:1998;176-180.
11. Nadeau K., Nadler S.G., Saulnier M., Tepper M.A., Walsh C.T. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry. 33:1994;2561-2567.
12. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
13. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 10:1994;405-455.
14. Joshi P.C., Grogan J.B., Thomae K.R. Effect of aminoguanidine on in vivo expression of cytokines and inducible nitric oxide synthase in the lungs of endotoxemic rats. Res. Commun. Mol. Pathol. Pharmacol. 91:1996;339-346.
15. Mattsson P., Zeevi A., Cai J., Yousem S.A., Hoffman R., Nalesnik M.et al. Effect of aminoguanidine and cyclosporine on lung allograft rejection. Ann. Thorac. Surg. 62:1996;207-212.
16. Griffiths M.J., Messent M., Curzen N.P., Evans T.W. Aminoguanidine selectively decreases cyclic GMP levels produced by inducible nitric oxide synthase. Am. J. Respir. Crit. Care Med. 152:1995;1599-1604.
17. Cetkovic-Cvrlje M., Eizirik D.L. TNF-alpha and IFN-gamma potentiate the deleterious effects of IL-1 beta on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine. 6:1994;399-406.
18. Kitabayashi K., Izumi R., Konishi K., Shimizu K., Miyazaki I. Increased graft survival by utilization of 15-deoxyspergualin in a canine pancreatic allotransplantation model. Eur. Surg. Res. 26:1994;54-61.
19. Yuh D.D., Morris R.E. The immunopharmacology of immunosuppression by 15-deoxyspergualin. Transplantation. 55:1993;578-591.
20. Hoeger P.H., Tepper M.A., Faith A., Higgins J.A., Lamb J.R., Geha R.S. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J. Immunol. 153:1994;3908-3916.
21. Dignam J.D., Levbovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
22. Kerr P.G., Atkins R.C. The effects of deoxyspergualin on lymphocytes and monocytes in vivo and in vitro. Transplantation. 48:1989;1048-1052.
23. Lan H.Y., Nikolic-Peterson D.J., Zarama M., Kerr P.G., Atkins R.C. Suppression of pulmonary injury in experimental 'Goodpasture's syndrome' by deoxyspergualin (DSP). Clin. Exp. Immunol. 95:1994;502-508.
24. Schafer R., Sheil J.M. Superantigens and their role in infectious disease. Adv. Pediatr. Infect. Dis. 10:1995;369-390.
25. Reda K.B., Kapur V., Mollick J.A., Lamphear J.G., Musser J.M., Rich R.R. Molecular characterization and phylogenetic distribution of the streptococcal superantigen gene (ssa) from Streptococcus pyogenes. Infect. Immun. 62:1994;1867-1874.
26. Dellabona P., Peccoud J., Kappler J., Marrack P., Benoist C., Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell. 62:1990;1115-1121.
27. Meyer O. Superantigens and their implication in autoimmune diseases. Presse Med. 24:1995;1171-1177.
28. Yokota S., Geppert T.D., Lipsky P.E. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J. Immunol. 140:1988;531.
29. Gery I., Gershon R.K., Waksman B.H. Potentiation of the T-lymphocyte response to mitogens: I. The responding cell. J. Exp. Med. 136:1972;128-142.
30. Scheurich P., Thoma B., Ucer U., Pifizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J. Immunol. 138:1987;1786-1790.
31. Bluestone J.A. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 2:1995;555-559.
32. Nemoto K., Abe F., Takita T., Nakamura T., Takeuchi T., Umezawa H. Suppression of experimental allergic encephalomyelitis in guinea pigs by spergualin and 15-deoxyspergualin. J. Antibiot. 40:1987;1193-1194.
33. Makino M., Fujiwara M., Aoyagi T., Umezawa H. Immunosuppressive activities of deoxyspergualin: II. The effect on the antibody responses. Immunopharmacology. 14:1988;115-121.
34. Nemoto K., Hayashi M., Sugawara Y., Ito J., Abe F., Takita T.et al. Biological activities of deoxyspergualin in autoimmune disease mice. J. Antibiot. 41:1988;1253-1259.
35. Nadler S.G., Tepper M.A., Schacter B., Mazzucco C.E. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science. 258:1992;484-486.
36. Heike M., Noll B., Meyer zum Buschenfelde K.H. Heat shock protein-peptide complexes for use in vaccines. J. Leukoc. Biol. 60:1996;153-158.
37. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 39:1994;93-98.
38. Barth W., Stochaj U. The yeast nucleoporin Nsp1 binds nuclear localization sequences in vitro. Biochem. Cell. Biol. 74:1996;363-372.
39. Paine P.L., Yassin R., Paine T.M., Vancurova I., George C., Sahay N. Intranuclear binding of nucleoplasmin. J. Cell. Biochem. 58:1995;105-114.
40. Shi Y., Thomas J.O. The transport of proteins into the nucleus requires the 70-kilodalton heat shock protein or its cytosolic cognate. Mol. Cell. Biol. 12:1992;2186-2192.
41. Diegel M.L., Moran P.A., Gilliland L.K., Damle N.K., Hayden M.S., Zarling J.M.et al. Regulation of HIV production by blood mononuclear cells from HIV-infected donors: II. HIV-1 production depends on T cell-monocyte interaction. AIDS Res. Hum. Retrovir. 9:1993;465-473.
42. Herman A., Croteau G., Sekaly R.-P., Kappler J., Marrack P. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J. Exp. Med. 172:1990;709-717.
43. Vabulas R., Bittlingmaier R., Heeg K., Wagner H., Miethke T. Rapid clearance of the bacterial superantigen staphylococcal enterotoxin B in vivo. Infect. Immun. 64:1996;4567-4573.
44. Toribio M.L., Gutierrez-Ramos J.C., Pezzi L., Marcos M.A., Martinez C. Interleukin-2-dependent autocrine proliferation in T-cell development. Nature. 342:1989;82-85.
45. Diamantstein T., Osawa H., Mouzaki A., Josimovic-Alasevic O. Regulation of interleukin-2 receptor expression and receptor release. Mol. Immunol. 23:1986;1165-1172.
46. Dickneite G., Schorlemmer H.U., Sedlacek H.H., Falk W., Ulrichs K., Muller-Ruchholtz W. Suppression of macrophage function and prolongation of graft survival by the new guanidinic-like structure, 15-deoxyspergualin. Transplant. Proc. 19:1987;1301-1304.
47. Hiltbold E.M., Ziegler H.K. Interferon-gamma and interleukin-10 have cross-regulatory roles in modulating the class I and class II MHC-mediated presentation of epitopes of Listeria monocytogenes by infected macrophages. J. Interferon Cytokine Res. 16:1996;547-554.
48. Barthelemy C., Liu Y.J. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int. Immunol. 6:1994;1177-1185.
49. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1991;1077-1082.